Whitespace Analysis

Find crowded markets, emerging opportunities, and underserved indications by trial activity and sponsor concentration.

Limited-time launch pricing

$99/month

30-day free trial - no credit card

Upgrade to Pro

Or explore free dashboards — PDUFA calendar, Trials Explorer, Biotechs, and more.

Competitive Density Analysis

Data updated: Nov 12, 2026

Trial activity, Phase 3 concentration, and competitive dynamics by indication

Current Metrics: Based on ClinicalTrials.gov data (active trials, phases, sponsors).

Future Enhancement: True "white space" analysis (trials vs approved drugs) requires mapping FDA-approved drugs to our indication taxonomy. FDA labels use specific terms like "HER2+ metastatic breast carcinoma" while our taxonomy uses broader categories like "Breast Cancer". This mapping is in progress.

Highest Trial Activity

Most active indications by total trial count

Indication	TA	Active Trials	Phase 3	Phase 2	Sponsors
Solid Tumor (Advanced)	Oncology	3712	402	1880	818
Non-Hodgkin Lymphoma	Oncology	1706	192	1085	230
Breast Cancer	Oncology	1588	338	942	202
NSCLC	Oncology	1551	299	929	337
Colorectal Cancer	Oncology	1215	203	767	244
Prostate Cancer	Oncology	909	168	533	158
AML	Oncology	711	83	373	117
Multiple Myeloma	Oncology	710	125	398	90
Pancreatic Cancer	Oncology	705	78	434	203
Hepatocellular Carcinoma	Oncology	654	98	399	121
Obesity	Metabolic	610	171	171	97
Lung Cancer (General)	Oncology	575	82	345	107
Hematologic Malignancies	Oncology	571	62	332	84
Ovarian Cancer	Oncology	568	95	300	172
Head and Neck Cancer	Oncology	562	59	353	153

Late-Stage Concentration

Highest Phase 3 activity (near-term competitive pressure)

Indication	TA	Phase 3	% of Trials	Active	Sponsors
Solid Tumor (Advanced)	Oncology	402	11%	3712	818
Breast Cancer	Oncology	338	21%	1588	202
NSCLC	Oncology	299	19%	1551	337
Colorectal Cancer	Oncology	203	17%	1215	244
Non-Hodgkin Lymphoma	Oncology	192	11%	1706	230
Stroke	Cardiovascular	174	44%	397	56
Obesity	Metabolic	171	28%	610	97
Prostate Cancer	Oncology	168	18%	909	158
Multiple Myeloma	Oncology	125	18%	710	90
Acute Pain	Pain	108	24%	446	47
Hypertension	Cardiovascular	98	28%	347	93
Hepatocellular Carcinoma	Oncology	98	15%	654	121

Concentrated Markets

Few sponsors running many trials (potential dominance or acquisition targets)

Indication	TA	Trials/Sponsor	Active	Sponsors
HIV	Infectious Disease	18.9	321	17
Postoperative Pain	Pain	16.6	199	12
Sepsis	Infectious Disease	16.6	116	7
PTSD	CNS	15.2	91	6
H. pylori	Infectious Disease	14.8	59	4
Alcohol Use Disorder	CNS	14	112	8
Chronic Pain	Pain	11.7	70	6
Atrial Fibrillation	Cardiovascular	11.5	138	12
Opioid Use Disorder	CNS	11.4	125	11
Overactive Bladder	Urology	11	33	3

Fragmented Markets

Many sponsors competing (crowded, potentially commoditized)

Indication	TA	Sponsors	Active	Phase 3
Solid Tumor (Advanced)	Oncology	818	3712	402
NSCLC	Oncology	337	1551	299
Colorectal Cancer	Oncology	244	1215	203
Non-Hodgkin Lymphoma	Oncology	230	1706	192
Pancreatic Cancer	Oncology	203	705	78
Breast Cancer	Oncology	202	1588	338
Ovarian Cancer	Oncology	172	568	95
Prostate Cancer	Oncology	158	909	168
Head and Neck Cancer	Oncology	153	562	59
Melanoma	Oncology	140	524	64

Showing the top indications in each category.

Methodology

Data Source: ClinicalTrials.gov (Phase 2-4 interventional drug trials, 2008+)

Active Trials: Status = Recruiting, Active, or Enrolling by Invitation

Trials/Sponsor: Average trials per company in that indication. Higher = concentrated market.

Phase 3 %: Proportion of active trials in Phase 3. Higher = more near-term competitive pressure.